Technology
Health
Pharmaceutical
CTI BioPharma
$1.029876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$1.02
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
$0.00 (0.00%) Today
+$0.01 (0.99%) After Hours
Why Robinhood?
You can buy or sell CTI BioPharma and other stocks, options, ETFs, and crypto commission-free!
About
CTI BioPharma Corp. operates as a biopharmaceutical company, which focuses on the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. Its products include PIXUVRI, Pacritinib, Tosedostat and Opaxio. Read More The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.
Employees
46
Headquarters
Seattle, Washington
Founded
1991
Market Cap
58.57M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
399.75K
High Today
$1.03
Low Today
$0.98
Open Price
$1.02
Volume
124.74K
52 Week High
$5.36
52 Week Low
$0.6001
Collections
Technology
Health
Pharmaceutical
Biopharmaceutical
2014 IPO
US
North America
News
PR NewswireMar 13
CTI BioPharma Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights
SEATTLE, March 13, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2018. "The Company is focused on advancing its development program of pacritinib for the treatment for myelofibrosis patients with severe thrombocytopenia in the United States and Europe in 2019," commented Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI BioPharma. "Following the previously-announced completion of full e...
Markets InsiderMar 13
EARNINGS SUMMARY: Details of CTI BioPharma Corp. Q4 Earnings Report
(RTTNews) - Below are the earnings highlights for CTI BioPharma Corp. (CTIC): -Earnings: $0.85 million in Q4 vs. -$14.27 million in the same period last year. -EPS: $0.01 in Q4 vs. -$0.33 in the same period last year. -Revenue: $14.11 million in Q4 vs. $0.46 million in the same period last year....
PR NewswireMar 12
CTI BioPharma to Present at Oppenheimer's 29th Annual Healthcare Conference on Tuesday, Mar. 19
SEATTLE, March 12, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at Oppenheimer's 29th Annual Healthcare Conference at 4:30 p.m. EDT at the Westin New York Grand Central. Presentation details: Event: Oppenheimer's 29th Annual Healthcare Conference Date: Tuesday, Mar. 19 Time: 4:30 p.m. EDT The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ct...
Price Paid on Robinhood
39% Lower
Right Now
52 Week Low
$0.6001
Average Price Paid
$1.68
52 Week High
$5.36
Earnings
-$0.33
-$0.21
-$0.09
$0.03
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.28 per share
Actual
$0.01 per share